We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassays Compared for Diagnosis of Acute Murine Typhus Infections

By LabMedica International staff writers
Posted on 10 Sep 2019
Print article
Image: A photomicrograph of an immunofluorescence assay (IFA) for Rickettsia (Photo courtesy of Fuller Laboratories).
Image: A photomicrograph of an immunofluorescence assay (IFA) for Rickettsia (Photo courtesy of Fuller Laboratories).
Murine typhus is a disease transmitted by fleas and is caused by intracellular gram-negative bacteria called Rickettsia typhi, and manifested clinically with acute fever, chills, muscle pain, nausea, vomiting, stomach pain, cough and rash.

Appropriate rapid diagnostics are needed to distinguish it from other infections, as patient management varies. Due to low rickettsemia during acute illness, the sensitivity of real-time polymerase chain reaction (PCR) is highly variable. Thus, sero-diagnosis using immunofluorescence assay (IFA) remains the gold standard.

Scientists working with the Indonesia Research Partnership on Infectious Disease (Jakarta, Indonesia) obtained samples from eight government referral teaching hospitals in seven provincial capitals. Paired acute and convalescent plasma samples from 40 cases with confirmed R. typhi and 58 controls with another confirmed infection were used to evaluate the performance of commercial IgM and IgG enzyme-linked immunosorbent assay (ELISA) and IFA. The 58 paired plasma specimens that they used for controls were negative for R. typhi and Rickettsia spp., but positive for other pathogens by culture or molecular testing.

The immunofluorescence assay (IFA) was performed using kits from Focus Diagnostics (Cypress, CA, USA). The dilution for study samples was 1:64, and for provided positive controls was 1:32. Acute and convalescent specimens from each subject were performed simultaneously. Acute and convalescent plasma were tested simultaneously using ELISA kits from Fuller Laboratories (Fullerton, CA, USA). Microwells were coated with the outer surface membrane protein rOmp B purified from R. typhi. Optical density (OD) was measured at a wavelength of 450 nm.

The team reported that sensitivity and specificity of combined ELISA IgM and IgG anti-R. typhi using paired specimens were excellent (95.0% and 98.3%, respectively), comparable to combined IFA IgM and IgG (97.5% and 100%, respectively); sensitivity of ELISA IgM from acute specimens only was poor (45.0%), but specificity was excellent (98.3%). IFA IgM was more sensitive (77.5%), but less specific (89.7%) for single specimens. IgM was detected as early as day three of fever by ELISA and day four by IFA. Starting from day nine of illness, IgM was detected in all cases by IFA, while ELISA missed two specimens (days 10 and 25).

The authors concluded that their data supports the validity of ELISA in the diagnosis of R. typhi infection. As the specificity in acute specimens as well as sensitivity and specificity in convalescent specimens and paired specimens were excellent, ELISA is recommended when fluorescence microscopy is not feasible. However, IFA remains the method of choice if resources are available. ELISA is appropriate for resource-limited settings as it is easy to read, is objective, and has a high throughput. The study was published on August 26, 2019, in the journal Vector-Borne and Zoonotic Diseases.

Related Links:
Indonesia Research Partnership on Infectious Disease
Focus Diagnostics
Fuller Laboratories

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Pathology

view channel
Image: The AI model accurately classifies pediatric sarcomas using digital pathology images alone (Photo courtesy of Shutterstock)

AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping

Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.